Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
275 stopped studies mapped to Malignant Urinary Tract Neoplasm and descendants · 93% state a reason
Over the 275 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02792192 | Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille… | Phase 1 / Phase 2 | terminated | Jun 7, 2016 | Hoffmann-La Roche | The study was terminated early as the study had met its goals of providing preliminary safety and… | Safety / toxicity |
| NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing… | Phase 3 | terminated | Sep 30, 2015 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT04273724 | Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment… | N/A | terminated | Feb 18, 2020 | UNC Lineberger Comprehensive Cancer Center | Investigator left and research was discontinued. | Investigator |
| NCT04280640 | Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical… | — | withdrawn | Feb 21, 2020 | UNC Lineberger Comprehensive Cancer Center | PI left UNC. | Investigator |
| NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants… | Phase 3 | terminated | Jul 21, 2017 | Spectrum Pharmaceuticals, Inc | Suspended development | Other (stated, no rule matched) |
| NCT03115801 | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic… | Phase 2 | terminated | Apr 14, 2017 | Weill Medical College of Cornell University | Lack of accrual | Enrollment / accrual |
| NCT04066595 | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.(CabUC) | Phase 2 | terminated | Aug 26, 2019 | Johannes Gutenberg University Mainz | Recruitment problems | Enrollment / accrual |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial… | Phase 2 | terminated | Feb 29, 2016 | M.D. Anderson Cancer Center | The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer. | Efficacy / futility |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | Phase 2 / Phase 3 | terminated | Sep 21, 2011 | CG Oncology, Inc. | Change in study design | Other (stated, no rule matched) |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth… | Phase 1 | terminated | Apr 24, 2017 | ADC Therapeutics S.A. | Safety | Safety / toxicity |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | terminated | Apr 13, 2018 | Baylor College of Medicine | The sponsor of this study has terminated the study due to poor enrollment. | Enrollment / accrual |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Phase 2 | terminated | Jun 23, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT04073160 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab…(TRIO Bladder) | Phase 1 | withdrawn | Aug 29, 2019 | Daniel George, MD | Study will not be completed. No participants were enrolled. | Enrollment / accrual |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT00350688 | Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy | N/A | terminated | Jul 11, 2006 | Ottawa Hospital Research Institute | More advanced treatments superceded study design | Other (stated, no rule matched) |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT03986398 | Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement…(Cranberry) | N/A | terminated | Jun 14, 2019 | Hopital Foch | In the perioperative setting of radical cystectomy-bladder replacement no improvement of UTI was… | Other (stated, no rule matched) |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive… | Phase 1 | withdrawn | Sep 13, 2019 | Tocagen Inc. | Sponsor decision. | Sponsor / business decision |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After… | Phase 1 / Phase 2 | terminated | Dec 12, 2013 | Heat Biologics | Inability to accrue due to changing treatment landscape (PD-1 approvals) | Enrollment / accrual |
| NCT01094496 | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive… | Phase 2 | terminated | Mar 29, 2010 | Celldex Therapeutics | Portfolio prioritization due to slow enrollment | Enrollment / accrual |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT03007719 | Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients… | Phase 2 | terminated | Jan 2, 2017 | Lawrence Fong | Low Accrual | Enrollment / accrual |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating… | Phase 2 | withdrawn | May 2, 2019 | Roswell Park Cancer Institute | no accrual | Enrollment / accrual |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2… | Phase 2 | withdrawn | Aug 1, 2019 | Dana-Farber Cancer Institute | Withdrawn per Bayer | Other (stated, no rule matched) |
| NCT00880854 | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | Phase 1 | withdrawn | Apr 14, 2009 | University of Wisconsin, Madison | Lack of accrual | Enrollment / accrual |
| NCT02365207 | Intravesical BCG Administration to Patients With Invasive Bladder Cancer | N/A | terminated | Feb 18, 2015 | The University of Texas Health Science Center at San Antonio | Poor accrual of subjects and lack of funding | Enrollment / accrual |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle… | Phase 2 | terminated | Jun 5, 2012 | Fox Chase Cancer Center | Extreme Toxicity | Safety / toxicity |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of… | — | terminated | Jul 10, 2015 | University of Southern California | The PI left institution | Investigator |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who… | Phase 1 / Phase 2 | terminated | Jun 3, 2014 | National Cancer Institute (NCI) | Slow, insufficient accrual. | Enrollment / accrual |
| NCT02202044 | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After… | N/A | terminated | Jul 28, 2014 | University of Colorado, Denver | The institution was requiring extensive changes to the protocol | Other (stated, no rule matched) |
| NCT03298958 | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive… | Phase 3 | withdrawn | Oct 2, 2017 | The University of Texas Health Science Center at San Antonio | No funding was received, no subjects were enrolled | Enrollment / accrual |
| NCT03029832 | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in… | Phase 2 | terminated | Jan 24, 2017 | Genentech, Inc. | The study was prematurely terminated due to slow patient accrual and discontinuation of clinical… | Enrollment / accrual |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | N/A | terminated | Mar 4, 2016 | University of Southern California | PI decided to revamp the protocol completely and will submit as new study. | Other (stated, no rule matched) |
| NCT01118351 | Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer | Phase 2 | terminated | May 6, 2010 | Case Comprehensive Cancer Center | not stated | Not stated |
| NCT03399643 | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable…(Announce) | — | terminated | Jan 16, 2018 | Hoffmann-La Roche | Tecentriq label restriction for first line limited the patient population and scientific question… | Other (stated, no rule matched) |
| NCT01060319 | A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies | — | withdrawn | Feb 2, 2010 | Stanford University | Business Decision | Sponsor / business decision |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in… | Phase 3 | withdrawn | May 8, 2015 | University of Southern California | No funding | Funding |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial… | Phase 2 | withdrawn | Feb 1, 2018 | University of California, San Francisco | Study withdrawn prior to patient enrollment | Enrollment / accrual |
| NCT02334527 | Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure… | Phase 2 | terminated | Jan 8, 2015 | UNC Lineberger Comprehensive Cancer Center | Data from first 12 subjects-primary endpoint not met. Data analysis underway. | Other (stated, no rule matched) |
| NCT03208712 | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases… | Early Phase 1 | terminated | Jul 5, 2017 | University of Michigan Rogel Cancer Center | Low accrual | Enrollment / accrual |
| NCT02605863 | Enzalutamide for Bladder Cancer Chemoprevention | Phase 2 | terminated | Nov 16, 2015 | University of Rochester | Low enrollment, sponsor withdrew support for study | Enrollment / accrual |
| NCT02145390 | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant… | N/A | terminated | May 22, 2014 | University of Miami | Investigator Decision - Insufficient Accrual | Investigator |
| NCT02700724 | Observation Versus Immediate Surgery of Low Risk Bladder Cancer | N/A | terminated | Mar 7, 2016 | Vanderbilt University Medical Center | poor enrollment | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 28, 2021source: clinicaltrials